Tempus AI, Inc. (NASDAQ:TEM) CEO Sells $5,428,601.64 in Stock

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CEO Eric P. Lefkofsky sold 80,388 shares of the business's stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $67.53, for a total value of $5,428,601.64. Following the completion of the transaction, the chief executive officer now directly owns 5,293,005 shares in the company, valued at approximately $357,436,627.65. The trade was a 1.50 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Tempus AI Stock Performance

Shares of NASDAQ TEM traded down $1.11 during trading on Monday, reaching $67.85. The company had a trading volume of 13,615,958 shares, compared to its average volume of 11,833,515. Tempus AI, Inc. has a twelve month low of $22.89 and a twelve month high of $79.49. The stock has a 50-day moving average price of $44.49 and a two-hundred day moving average price of $49.16. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on TEM shares. Piper Sandler restated a "neutral" rating and issued a $70.00 price target (up from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Wolfe Research started coverage on Tempus AI in a research note on Friday, December 13th. They issued an "outperform" rating and a $60.00 price target on the stock. Loop Capital decreased their price target on Tempus AI from $57.00 to $52.00 and set a "buy" rating on the stock in a research note on Tuesday, January 14th. TD Cowen reiterated a "buy" rating and set a $74.00 target price (up from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $56.00 target price on shares of Tempus AI in a research report on Tuesday, January 14th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, Tempus AI currently has an average rating of "Moderate Buy" and a consensus price target of $58.55.

Hedge Funds Weigh In On Tempus AI

Institutional investors have recently made changes to their positions in the stock. ARK Investment Management LLC increased its stake in Tempus AI by 132.1% in the fourth quarter. ARK Investment Management LLC now owns 5,519,644 shares of the company's stock valued at $186,343,000 after purchasing an additional 3,141,487 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its stake in Tempus AI by 166.0% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,239,093 shares of the company's stock valued at $109,352,000 after purchasing an additional 2,021,394 shares during the last quarter. NEA Management Company LLC increased its stake in Tempus AI by 17.8% in the third quarter. NEA Management Company LLC now owns 5,385,979 shares of the company's stock valued at $304,846,000 after purchasing an additional 813,169 shares during the last quarter. Millennium Management LLC acquired a new position in Tempus AI in the second quarter valued at $8,067,000. Finally, Carnegie Investment Counsel acquired a new position in Tempus AI in the third quarter valued at $7,936,000. 24.22% of the stock is owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.